Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Certara (Nasdaq: CERT), a leader in model-informed drug development, has appointed Dr. Christopher Bouton as Chief Technology Officer. Dr. Bouton, founder and former CEO of Vyasa Analytics (acquired by Certara in 2022), will spearhead the development of a next-generation integrated model-informed drug development platform powered by generative AI and biosimulation technology.
Dr. Bouton's background includes founding Entagen (acquired by Thomson Reuters) and experience as a computational biologist at Pfizer. He has already led the development of several Certara AI-based products, including CoAuthor™, a generative AI solution for regulatory and medical writing.
Certara (Nasdaq: CERT), leader nello sviluppo di farmaci basato su modelli, ha nominato Dr. Christopher Bouton come Chief Technology Officer. Il Dr. Bouton, fondatore ed ex CEO di Vyasa Analytics (acquisita da Certara nel 2022), guiderà lo sviluppo di una piattaforma integrata di nuova generazione per lo sviluppo di farmaci basato su modelli, alimentata da intelligenza artificiale generativa e tecnologia di biosimulazione.
Il background del Dr. Bouton include la fondazione di Entagen (acquisita da Thomson Reuters) e l’esperienza come biologo computazionale presso Pfizer. Ha già guidato lo sviluppo di diversi prodotti Certara basati su AI, tra cui CoAuthor™, una soluzione di intelligenza artificiale generativa per la scrittura regolatoria e medica.
Certara (Nasdaq: CERT), líder en desarrollo de fármacos basado en modelos, ha nombrado a Dr. Christopher Bouton como Director de Tecnología. El Dr. Bouton, fundador y ex CEO de Vyasa Analytics (adquirida por Certara en 2022), liderará el desarrollo de una plataforma integrada de próxima generación para el desarrollo de fármacos basado en modelos, impulsada por inteligencia artificial generativa y tecnología de biosimulación.
El Dr. Bouton tiene experiencia fundando Entagen (adquirida por Thomson Reuters) y como biólogo computacional en Pfizer. Ya ha liderado el desarrollo de varios productos de Certara basados en IA, incluyendo CoAuthor™, una solución de inteligencia artificial generativa para redacción regulatoria y médica.
Certara (나스닥: CERT)는 모델 기반 약물 개발 분야의 선두주자로, Dr. Christopher Bouton을 최고기술책임자(CTO)로 임명했습니다. Dr. Bouton은 Vyasa Analytics의 창립자이자 전 CEO로, 해당 회사는 2022년에 Certara에 인수되었습니다. 그는 생성형 AI와 바이오시뮬레이션 기술을 활용한 차세대 통합 모델 기반 약물 개발 플랫폼 개발을 이끌 것입니다.
Dr. Bouton은 Thomson Reuters에 인수된 Entagen 설립자이며, Pfizer에서 계산생물학자로 근무한 경력이 있습니다. 또한 그는 Certara의 여러 AI 기반 제품 개발을 주도했으며, 그 중에는 규제 및 의료 문서 작성을 위한 생성형 AI 솔루션인 CoAuthor™가 포함되어 있습니다.
Certara (Nasdaq : CERT), leader dans le développement de médicaments basé sur des modèles, a nommé Dr. Christopher Bouton au poste de Directeur Technique. Dr. Bouton, fondateur et ancien PDG de Vyasa Analytics (acquise par Certara en 2022), dirigera le développement d'une plateforme intégrée de nouvelle génération pour le développement de médicaments basé sur des modèles, alimentée par l'intelligence artificielle générative et la technologie de biosimulation.
Le parcours du Dr. Bouton inclut la fondation d'Entagen (acquise par Thomson Reuters) et une expérience en tant que biologiste computationnel chez Pfizer. Il a déjà piloté le développement de plusieurs produits Certara basés sur l'IA, y compris CoAuthor™, une solution d'IA générative pour la rédaction réglementaire et médicale.
Certara (Nasdaq: CERT), ein führendes Unternehmen im modellgestützten Arzneimittelentwicklungsbereich, hat Dr. Christopher Bouton zum Chief Technology Officer ernannt. Dr. Bouton, Gründer und ehemaliger CEO von Vyasa Analytics (im Jahr 2022 von Certara übernommen), wird die Entwicklung einer integrierten, nächsten Generation von modellgestützten Arzneimittelentwicklungsplattformen leiten, die von generativer KI und Biosimulations-Technologie angetrieben wird.
Dr. Bouton hat Entagen gegründet (von Thomson Reuters übernommen) und war als computergestützter Biologe bei Pfizer tätig. Er hat bereits die Entwicklung mehrerer KI-basierter Produkte von Certara geleitet, darunter CoAuthor™, eine generative KI-Lösung für regulatorisches und medizinisches Schreiben.
- None.
- None.
Insights
Certara's appointment of Dr. Bouton as CTO strengthens their AI capabilities in drug development, positioning them competitively in biosimulation technology.
Certara's appointment of Dr. Chris Bouton as CTO represents a strategic reinforcement of the company's commitment to AI-powered drug development solutions. This isn't merely a personnel change but a calculated move to accelerate their technological evolution in the competitive biosimulation market.
Dr. Bouton brings particularly valuable credentials to this role, having founded Vyasa Analytics (acquired by Certara in 2022) and previously Entagen (acquired by Thomson Reuters). His track record shows a pattern of building and scaling AI solutions specifically for life sciences applications, with recent success developing Certara's CoAuthor™ generative AI product for regulatory writing.
The announcement signals Certara's intensified focus on integrating advanced AI with their existing biosimulation platform. This integration addresses a critical industry pain point – the time and cost inefficiency in traditional drug development. By consolidating their scientific expertise with AI capabilities, Certara is positioning to deliver enhanced value through what they're calling a "next-generation integrated model-informed drug development platform."
The emphasis on using this technology to "speed timelines, reduce costs, and improve success rates" speaks directly to the pharmaceutical industry's most pressing challenges. If successfully executed, this strategy could strengthen Certara's competitive position by offering clients measurable efficiency gains in an industry where development timelines often extend over a decade and costs frequently exceed
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology.
Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data sources. Chris has led the development of several new Certara AI-based products, including CoAuthor ™, a generative AI product for regulatory and medical writing. Earlier in his career, Chris founded and led Entagen, an enterprise analytics software provider acquired by Thomson Reuters, and started his work in drug development as a computational biologist at Pfizer.
“Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development,” said William F. Feehery, Chief Executive Officer. “His leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.
Certara’s next-generation modeling platform integrates its scientific expertise, broad portfolio of solutions, and AI approaches to increase the efficiency and effectiveness of discovering and developing novel therapeutics.
“Biosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates,” said Bouton. “Leading Certara’s technology strategy to build the industry’s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.”
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
Who is Certara's new Chief Technology Officer?
What is Dr. Bouton's role at Certara (CERT)?
What is Dr. Christopher Bouton's background before joining Certara?
What AI products has Dr. Bouton developed at Certara?
How will AI integration impact Certara's drug development process?
